Navigation Links
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Date:2/7/2008

d HIV-1 strains resistant to a NNRTI and other ARV agents.

This indication is based on Week 24 analyses from two randomized, double- blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

-- Treatment history and, when available, resistance testing, should guide

the use of INTELENCE.

-- The use of other active antiretroviral agents with INTELENCE is

associated with an increased likelihood of treatment response.

-- In patients who have experienced virologic failure on an

NNRTI-containing regimen, do not use INTELENCE in combination with

only N[t]RTIs.

-- The risks and benefits of INTELENCE have not been established in

pediatric patients or in treatment-nave adult patients.

DUET-1 and -2 Study Design

The DUET-1 and -2 studies, identical in design but conducted in different regions, assessed the 24- and 48-week efficacy and safety of INTELENCE in combination with a BR in treatment-experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. The primary endpoint was the proportion of patients who achieved a confirmed undetectable viral load (less than 50 copies/mL)

Patients with HIV-1 who were eligible for the DUET studies had a viral load of greater than 5,000 copies/mL while on a stable antiretroviral therapy regimen for at least eight weeks and had evidence of at least one NNRTI- resistance-associated mutation, either at screening or from prior resistance tests, as well as evidence of three or more primary PI mutations (D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M) at screening.

Participants in the DUET studies were randomized to receive INTELENCE 200 mg twice daily (599 patients) or pl
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
3. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
6. Vanda Presents Phase III Iloperidone Efficacy Data
7. Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
8. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
11. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , 1. September 2015 In nur ... 2.500 Mitarbeitern hat die SHL Group schnell weltweit ... und rapides Wachstum auf dem Markt der ... Produktivität und das Management von SHL wieder. ... SHL ist weltweit führend in Design und Herstellung ...
(Date:9/1/2015)... 31, 2015 Research and Markets ( ... "Introduction to Veterinary Pharmacovigilance (London, UK - ... This course has been designed to ... those concerned with Veterinary Pharmacovigilance. New entrants, support ... a better understanding of veterinay drug safety will ...
(Date:9/1/2015)... 1, 2015 Egalet Corporation (Nasdaq: ... company focused on discovering, developing, and commercializing innovative ...  presenting scientific data on SPRIX ® (ketorolac ... morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, ... 2015 to be held September 8 to ...
Breaking Medicine Technology:SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6
(Date:9/1/2015)... ... September 01, 2015 , ... ... Extension Vending Machine,” is still strongly maintaining her firm’s success in the hair ... tools. In her upcoming city-to-city tour, Ellis will be providing “Look and learn” ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit the patients ... Valley Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, ... programs and services designed to support patients and their families during their time at ...
(Date:9/1/2015)... ... 01, 2015 , ... e-Spirit Inc., a leading supplier of ... Content Management System with new capabilities and enhancements designed to support the recently ... be well on their way to achieving digital transformation with less time and ...
(Date:9/1/2015)... ... , ... The FSH Society , the Massachusetts-based charity that has transformed ... the beneficiary of a collection of fundraising events this fall. From Boston to Los ... Society and further FSHD research. , The list of 2015 fall events ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO has announced an upcoming ... requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This ... , Calibration, qualification, and the appropriate level of routine testing for laboratory ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... Teen the Chance to be drawn into a ... Batman comic ... living a dual life is no easy task. Along with exercise and,eating ... after a night spent defeating Gotham City,s most evil villains., (Photo: ...
... to Retire from Company, INDIANAPOLIS, May 28 ... of its Operations, Technology and,Government Services unit based ... executive officer of that organization. Effective July 1, ... will not be replacing him,in that role., ...
... $60 million over 11 years , , WEDNESDAY, May 28 (HealthDay ... belts significantly reduces injuries to the brain, face, spine and ... rates, injury severity and hospital-acquired infections among crash patients, says ... use of air bags could reduce the use of resources ...
... A study released today reveals a cellular mechanism involved ... issue of The Journal of Neuroscience, shows that gabapentin, ... reduces alcohol intake in alcohol-dependent rats by normalizing chemical ... abuse. , The central amygdala, a part of the ...
... NEW YORK, May 28 Responding to the decline ... the past four trading days,Robin Smith, CEO, NeoStem said, ... would lead to the sudden decline in our share ... 21, 2008, we received a,private placement financing in a ...
... CHUM and MUHC migration to complete electronic records, ... Solutions, Inc. (Nasdaq: STRM ) and Emergis ... an integrated document management and,workflow solution at the ... Montreal (CHUM) and the McGill University,Health Centre (MUHC). ...
Cached Medicine News:Health News:Batman Takes on Gotham City With a Little Help From Milk 2Health News:WellPoint Announces Realignment of Operations, Technology and Government Services Unit 2Health News:Air Bags-Seat Belts Cut Injuries, Deaths, Costs 2Health News:New study reveals brain cell mechanism of alcohol dependence 2Health News:NeoStem, Inc. Comments on Recent Selling Pressure 2Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 2Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 3Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 4Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 5
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Gillies (Converse) Skin Hook, small hook size....
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Medicine Products: